Wichterman Troy, Chief Financial Officer of BioLife Solutions (BLFS), has demonstrated a consistent pattern of selling company stock over the past two years, with no recorded purchases in SEC filings. Since March 2024, Troy has executed 19 sales totaling approximately $1.94 million, with transactions ranging from smaller dispositions—such as a $2,550 sale on May 17, 2024—to larger ones, including a $771,600 sale on December 4, 2025, and a $578,141 transaction on February 24, 2026. The sales have been frequent, with multiple disposals occurring in concentrated periods, such as three separate transactions in February 2026 alone.
Notably, the majority of Troy’s recent activity has been outright sales (coded "S"), with only a few filings related to derivative transactions (coded "F") or awards (coded "A"), which carried no reported value. The absence of any buy transactions suggests a one-way disposition trend, though the reasons remain undisclosed in the filings. The largest single sale occurred in late 2025, followed by another significant disposal in early 2026, indicating sustained liquidity events rather than isolated exits. Given the CFO’s role, the transactions are closely monitored, but the filings provide no indication of material non-public information influencing the sales. The activity remains confined to BLFS, with no trades in other securities.
AI-assisted summary